Press coverage about Strongbridge Biopharma (NASDAQ:SBBP) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Strongbridge Biopharma earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.0681794784812 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
SBBP has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Strongbridge Biopharma in a research report on Wednesday, November 15th. Zacks Investment Research raised Strongbridge Biopharma from a “sell” rating to a “hold” rating and set a $7.25 price target on the stock in a research report on Wednesday, October 11th. Oppenheimer initiated coverage on Strongbridge Biopharma in a research report on Thursday, August 10th. They set an “outperform” rating and a $12.00 price target on the stock. Finally, ValuEngine downgraded Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $11.81.
Shares of Strongbridge Biopharma (NASDAQ:SBBP) opened at $6.30 on Tuesday. Strongbridge Biopharma has a 12-month low of $2.00 and a 12-month high of $8.85. The company has a debt-to-equity ratio of -1.89, a current ratio of 4.70 and a quick ratio of 4.61.
TRADEMARK VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/12/05/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-strongbridge-biopharma-plc-sbbp-stock-price.html.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma plc and related companies with MarketBeat.com's FREE daily email newsletter.